Financial Tearsheet

Company Overview

Tenax Therapeutics Inc (NASDAQ:TENX)

Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. 

Stock Performance

Today's Open 0.5410
Volume 99,336
Day Range 0.5025 - 0.5410
52 Week Range 0.4150 - 2.8400
Bid/Ask 0.5200 / 0.5300
Bid/Ask Size 1,700 X 4,500
Previous Close 0.5490
Market Cap 14.9 million
Shares Outstanding 28.12 million
Dividend/Yield 0.0000 / 0.0000%
EPS (TTM) 0.530103
P/E Ratio (TTM) 0.9998

Recent XBRL Filings

Filing Date Form Type Description View
Mar 16, 2017 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 09, 2016 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 09, 2016 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 10, 2016 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Dec 10, 2015 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Michael B. Jebsen, Interim CEO, Chief Financial Officer

Douglas Hay, PhD, EVP of Regulatory Affairs

Nancy Hecox, EVP, Legal Affairs, General Counsel, and Corporate Secretary

Doug Randall, EVP of Commercial and Business Operations

Board of Directors

Dr. Ronald Blanck, Chairman

John Kelley, Chief Executive Officer

Anthony DiTonno, Director

James Mitchum, Director

Gregory Pepin, Director

Gerald Proehl, Director

Chris A. Rallis, Director